The European Commission has issued marketing authorization for once-daily oral semaglutide 25 mg tablets, marketed under the Wegovy brand, for the management of obesity and weight-associated comorbidities in adults. This regulatory milestone marks the introduction of the first GLP-1 receptor agonist in oral form for weight management within the European Union, extending the drug’s existing presence in the United States, the United Kingdom, the United Arab Emirates, and Bahra

Key Regulatory Proposals Aetna, a CVS Health company, has released the results of its second quarterly Provider Survey, highlighting a notable shift in the relationship between healthcare payers and providers. According to the data, the average provider trust score for payers has increased to 6.1, up from 5.4 in the first quarter of the year. Approximately 38% of survey participants now rate their payer partners an 8 or higher on a 10-point scale. Operational improvements app